文献速递眼底病与葡萄膜炎青光眼白内障与屈光手术

四种最常见眼病的临床试验与系统评价结局比较

Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项横断面研究分析了截至2016年7月20日发表的56篇Cochrane系统评价及其纳入的414项试验,覆盖年龄相关性黄斑变性、白内障、糖尿病视网膜病变和青光眼。结果显示多数系统评价结局在试验中有报告,但多数试验结局未在系统评价中报告,仅视力一项在超过半数试验和评价中一致报告。

要点

  • 多数系统评价结局也在试验中报告,比例从糖尿病视网膜病变的14/19(73.7%)到白内障的27/29(93.1%)。
  • 试验结局在系统评价中报告的比例低,从年龄相关性黄斑变性的19/107(17.8%)到青光眼的24/89(27.0%)。
  • 仅视力一项结局在超过半数试验和超过半数系统评价中一致报告。

核心结论

  • 多数系统评价结局在试验中有报告,但多数试验结局未在系统评价中报告。
  • 试验结局的不一致性可能妨碍研究合成,提示眼科需要疾病特异性核心结局集。

研究设计与样本

  • 横断面研究,纳入截至2016年7月20日发表的针对年龄相关性黄斑变性、白内障、糖尿病视网膜病变和青光眼的全部Cochrane系统评价,且每篇至少纳入1项试验,共56篇系统评价、414项试验。
  • 每种疾病由一对临床专家独立分类所有结局并解决分歧,然后按疾病分别比较结局。

主要发现

  • 每种疾病的每项试验和每篇系统评价的结局中位数均为5个。
  • 试验总体结局数多于系统评价,范围为2.9倍(青光眼89 vs 30个结局)至4.9倍(年龄相关性黄斑变性107 vs 22个结局)。
  • 多数系统评价结局也在试验中报告,从糖尿病视网膜病变的14/19(73.7%)到白内障的27/29(93.1%)。
  • 试验结局在系统评价中报告的比例低,从年龄相关性黄斑变性的19/107(17.8%)到青光眼的24/89(27.0%)。
  • 仅视力一项结局在超过半数试验和超过半数系统评价中一致报告。

关键数值与推荐

  • 系统评价结局在试验中报告的比例:糖尿病视网膜病变14/19(73.7%),白内障27/29(93.1%)。
  • 试验结局在系统评价中报告的比例:年龄相关性黄斑变性19/107(17.8%),青光眼24/89(27.0%)。
  • 试验与系统评价结局总数比较:青光眼89 vs 30(2.9倍),年龄相关性黄斑变性107 vs 22(4.9倍)。
  • 每项试验和每篇系统评价的结局中位数均为5个。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 当前分析聚焦于结局域,可能低估结局不一致的问题。
  • 结局的其他重要要素(即具体测量、具体指标、聚合方法和时间点)可能不同,即使结局域重叠。
  • 试验结局的不一致性可能妨碍研究合成,提示眼科需要疾病特异性核心结局集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Suboptimal overlap in outcomes reported in clinical trials and systematic reviews compromises efforts to compare and summarize results across these studies. OBJECTIVES: To examine the most frequent outcomes used in trials and reviews of the 4 most prevalent eye diseases (age-related macular degeneration [AMD], cataract, diabetic retinopathy [DR], and glaucoma) and the overlap between outcomes in the reviews and the trials included in the reviews. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study examined all Cochrane reviews that addressed AMD, cataract, DR, and glaucoma; were published as of July 20, 2016; and included at least 1 trial and the trials included in the reviews. For each disease, a pair of clinical experts independently classified all outcomes and resolved discrepancies. Outcomes (outcome domains) were then compared separately for each disease. MAIN OUTCOMES AND MEASURES: Proportion of review outcomes also reported in trials and vice versa. RESULTS: This study included 56 reviews that comprised 414 trials. Although the median number of outcomes per trial and per review was the same (n = 5) for each disease, the trials included a greater number of outcomes overall than did the reviews, ranging from 2.9 times greater (89 vs 30 outcomes for glaucoma) to 4.9 times greater (107 vs 22 outcomes for AMD). Most review outcomes, ranging from 14 of 19 outcomes (73.7%) (for DR) to 27 of 29 outcomes (93.1%) (for cataract), were also reported in the trials. For trial outcomes, however, the proportion also named in reviews was low, ranging from 19 of 107 outcomes (17.8%) (for AMD) to 24 of 89 outcomes (27.0%) (for glaucoma). Only 1 outcome (visual acuity) was consistently reported in greater than half the trials and greater than half the reviews. CONCLUSIONS AND RELEVANCE: Although most review outcomes were reported in the trials, most trial outcomes were not reported in the reviews. The current analysis focused on outcome domains, which might underestimate the problem of inconsistent outcomes. Other important elements of an outcome (ie, specific measurement, specific metric, method of aggregation, and time points) might have differed even though the domains overlapped. Inconsistency in trial outcomes may impede research synthesis and indicates the need for disease-specific core outcome sets in ophthalmology.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Saldanha IJ, Lindsley K, Do DV, et al. Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases. JAMA Ophthalmol. 2017. PMID: 28772305. doi:10.1001/jamaophthalmol.2017.2583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。